Fulcrum Therapeutics, Inc. ― Announced results from the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of...
Therapeutics
Phase 2b study completed in amyotrophic lateral sclerosis (ALS) demonstrated lead asset PrimeC slows disease progression and functional decline Ongoing...
